Novo Nordisk

#Collaboration #Drug delivery #Nanexa #Novo Nordisk #Peptides

Novo and Nanexa agree €1.165 billion drug delivery deal

A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases.  The collaboration includes development of long-acting injectable formulations with different administration-frequency profiles, with monthly… Read More

#Business & Investment #News

Novo Nordisk head office
#Anthropic #Artificial intelligence (AI) #Cardiometabolic diseases #Collaboration #Novo Nordisk

New deals boost Novo Nordisk’s AI drug discovery ambitions

Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases.   Under the terms of the agreement, Orbis Medicines is eligible to receive up to $1.4 billion in upfront and potential development and commercial milestone payments, in addition… Read More

#Business & Investment #News

Cell and gene therapy concept
#Cell and gene therapy #Eli Lilly #FDA #Novo Nordisk #Takeda #Tregs

A bright future for advanced therapies 

2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This, alongside… Read More

#Exclusive Content

Boy tests his blood sugar levels at home
#GLP-1 #Novo Nordisk #Paediatrics #Phase III trial #Type 2 diabetes

Semaglutide could be first oral GLP-1 RA therapy for children

Positive topline results from Novo Nordisk’s PIONEER TEENS, a Phase IIIa trial evaluating oral semaglutide for type 2 diabetes demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo.  The trial, in children and adolescents aged 10–17 years with type 2 diabetes, also… Read More

#News

Novo Nordisk head office
#Artificial intelligence (AI) #Collaboration #Drug discovery #Novo Nordisk #OpenAI

Novo Nordisk partners with OpenAI across operations

Novo Nordisk has announced a strategic partnership with OpenAI that it hopes will place the company at the forefront of AI transformation in healthcare and help it bring new and better treatment options to patients faster.  The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug… Read More

#Business & Investment #News

Novo Nordisk head office
#Adverse event #FDA #GLP-1 #Novo Nordisk #Obesity #Ozempic

Novo receives FDA warning, strikes deal with Hims & Hers

Novo Nordisk has received a Warning Letter from the US Food and Drug Administration (FDA) related to violations of postmarketing adverse drug experience (PADE) regulations.  The letter relates to an inspection that took place in early 2025, in which the FDA found serious violations of PADE reporting requirements, in response… Read More

#Business & Investment #News #Regulatory #Trending News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#Collaboration #Metabolic diseases #Novo Nordisk #Vivtex

Novo Nordisk and Vivtex partner on oral metabolic therapies

Novo Nordisk and Vivtex Corporation have announced a partnership to develop oral biologic medicines for obesity, diabetes and associated comorbidities.  Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront payments totalling up to $2.1 billion, and tiered royalties on… Read More

#Business & Investment #News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

Scales showing a comparison between Mounjaro and Ozempic
#GLP-1 #Novo Nordisk #Obesity #Weight loss

Head-to-head obesity trial disappointment for Novo Nordisk 

Novo Nordisk has seen a significant fall in its stock value following disappointing trial results for its obesity treatment CagriSema, which is a fixed dose combination of cagrilintide 2.4mg and semaglutide 2.4mg.  Although CagriSema demonstrated 23% weight loss in the open-label head-to-head Phase III REDEFINE 4 trial,… Read More

#News #Trending News

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

DDW Highlights: 24 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More

#Podcasts

#Biosimilars #Cancer research #Cancer Research Horizons #Cerebral Palsy #Clinical trial #Crohn's disease #Depression #European Union #Novo Nordisk #Obesity #Psychedelics #Thermo Fisher Scientific #Ulcerative colitis (UC)

This week in Drug Discovery (16 – 20 February) 

News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW.  This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy.  The top stories:    Psychedelic drug could help treat depression … Read More

#News

Weight loss concept
#European Commission #Novo Nordisk #Obesity

Higher dosage of Wegovy more effective for weight loss 

The European Commission (EC) has approved a higher dosage of obesity drug Wegovy which has proved it can help adults lose weight more effectively.  Final approval has been granted to a new 7.2mg once-weekly maintenance dose of Wegovy (semaglutide injection), giving doctors another treatment option alongside the previous 2.4mg dose.   Novo… Read More

#News #Regulatory

FDA
#FDA #GLP-1 #Novo Nordisk #Obesity #Weight loss

FDA approves first oral GLP-1 for weight management

The US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.  The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy… Read More

#News #Regulatory #Trending News

#Alzheimer's #GLP-1 #Neurodegenerative disorders #Novo Nordisk #Obesity

Semaglutide shows no benefit in Alzheimer’s disease

Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer's disease progression.  The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic Alzheimer’s disease were… Read More

#Business & Investment #News #Trending News

Metsera logo
#Mergers and acquisitions #Metsera #Novo Nordisk #Obesity #Pfizer #Weight loss

Pfizer finally wins bidding war to acquire Metsera

Following a week-long bidding war with Novo Nordisk, Pfizer has acquired obesity drug specialists Metsera for $10 billion, thanks to an intervention by the US Federal Trade Commission (FTC).  Metsera's Board of Directors unanimously recommended that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the… Read More

#Business & Investment #News #Trending News